Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Derek Raghavan Explains How Use of Guidelines Can Address Issues of Cost and Variation

Guidelines can help address issues of cost and variation, especially in complex diseases, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.


Guidelines can help address issues of cost and variation, especially in complex diseases, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

Transcript

What is the importance of implementing evidence-based guidelines for complex diseases, such as hematological malignancies?

One of the big problems in managing hematological malignancies is the rapidly burgeoning costs. The costs are from the new diagnostic tests that are tremendously expensive, the new targeted therapies that are even more expensive, and the fact that diagnostic companies and pharmaceutical companies are increasingly looking to make profits and going to the bottom line. And there’s a tension between that and the payers, who are increasingly looking to reduce expenditure.

One of the ways of getting around this is to structure guidelines that will take into account the best evidence base of what we do, if, for example, there are 2 agents that are equally active against a particular malignancy, then obviously physicians and patients will want to use the one that is less toxic. If these agents are equiactive, in other words have the same success rate and the same level of toxicity, then we need to be moving to the agents that are less expensive. And pharmaceutics committees are increasingly looking at that algorithm.

In the design of clinical guidelines and clinical pathways, what we have to do is overcome unnecessary variation. At the Levine Cancer Institute, where I work, we’ve actually created a mechanism where we’ve developed a series of electronically accessible pathways. They can be modified electronically, they’re created by a series of tumor-specific teams based on level 1 evidence. And, so, for every type of disease, we have a structured approach of preferred treatments, acceptable treatments, and treatments that we will not use.

Now, the trick is trying to make sure that our physicians use those treatments. There are a number of ways of incentivizing physicians. One is just simply making them do the right thing. If they’re reluctant to do that, then you can actually put financial penalties in place. As a rule, physicians are competitive and want to get the best results. So, I would anticipate over the ensuing years, with increasing pressures of cost, increasing stringency of oversight, physicians will increasingly adopt guidelines. And the reality is, if that doesn’t happen, the payers will ensure that it goes in that direction.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!